Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s forecast for CRB-913 peak sales has been lowered to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback